Vectory Therapeutics secured FDA IND clearance for VTX‑002, a first‑in‑class vectorized antibody targeting TDP‑43 pathology in amyotrophic lateral sclerosis (ALS). The company said PIONEER‑ALS, a Phase I/II trial, can proceed to evaluate safety, dosing and early biomarker signals in patients with TDP‑43‑driven disease. Vectory positioned VTX‑002 as a targeted approach to a common pathological driver across sporadic and familial ALS cases. The IND clearance allows the company to initiate clinical dosing and biomarker assessments to establish target engagement in the CNS. The program represents one of several emerging efforts to address TDP‑43 aggregation and could inform future combination strategies in neurodegeneration.